TargImmune Therapeutics AG is a private Swiss-based biotechnology firm focused on drug development using novel targeted immunotherapies.
TargImmune Therapeutics AG
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/targimmune-therapeutics-ag” connections=”true” suffix=””]
The TargImmune technology platform known as CTPIC (ÇCancer Targeted delivery of pIC), was in-licensed from the Hebrew University of Jerusalem, encompasses a proprietary non-viral vector to target receptors that are overexpressed on cancer cells. Once at the target cell, the vector delivers an immune-modulating agent (poly-IC or pIC) into the cell, which then triggers apoptosis (programmed cell death) and an immune response against the cancer.
In July 2017, Race Oncology Limited (ASX: RAC) and TargImmune Therapeutics forms a new joint venture company called Race Immunotherapeutics, to focus on developing new and improved cancer therapies based on combining Bisantrene (Races cancer chemotherapy drug) with TargImmunes targeted cancer therapy technology. The new company is equally owned by both companies with core development work to be conducted by TargImmune scientists in Basel.